We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+53.94%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$2.09B
AUM Growth
+$380M
Cap. Flow
-$160M
Cap. Flow %
-7.66%
Top 10 Hldgs %
62.79%
Holding
58
New
9
Increased
13
Reduced
12
Closed
10

Top Buys

Rank Stock Value
1
EYPT icon
EyePoint Inc
EYPT
+$31.7M
2
ALXO icon
ALX Oncology
ALXO
+$24M
3
ABVX
Abivax
ABVX
+$21.7M
4
CRGX
CARGO Therapeutics
CRGX
+$20.1M
5
AUTL
Autolus Therapeutics
AUTL
+$19.3M

Top Sells

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$69.8M
2
GPCR icon
Structure Therapeutics
GPCR
+$53.3M
3
CABA icon
Cabaletta Bio
CABA
+$43.8M
4
BBIO icon
BridgeBio Pharma
BBIO
+$39.6M
5
CBAY
Cymabay Therapeutics
CBAY
+$36.5M

Sector Composition

Rank Sector Weight
1 Healthcare 98.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELVN icon
51
Enliven Therapeutics
ELVN
$4.43B
– –
-1,216,712
Closed -$16.6M
ERAS icon
52
Erasca
ERAS
$6.39B
– –
-10,813,246
Closed -$21.3M
GPCR icon
53
Structure Therapeutics
GPCR
$3.78B
– –
-1,056,373
Closed -$53.3M
RNAM
54
DELISTED
Avidity Biosciences
RNAM
– –
-1,762,115
Closed -$11.2M
VIGL
55
DELISTED
Vigil Neuroscience
VIGL
– –
-616,786
Closed -$3.32M
ZNTL icon
56
Zentalis Pharmaceuticals
ZNTL
$302M
– –
-700,000
Closed -$14M
KRTX
57
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
– –
-140,000
Closed -$23.7M
ORTX
58
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
– –
-25,664
Closed -$198K
1 2
3

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q4 2023 Portfolio in Review

As of Q4 2023, Cormorant Asset Management held 58 positions worth $2.09B, up 22% from $1.71B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Cormorant Asset Management withdrew a net $160M in Q4 2023, closing 10 positions and reducing 12 holdings. Its most notable exit was Structure Therapeutics, an estimated $53.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier.

Against the trend, Cormorant Asset Management opened a new position in Abivax worth $22.8M.

  • Cormorant Asset Management's largest Q4 2023 buy was Abivax: 2,130,000 shares worth $22.8M.
  • Cormorant Asset Management added most to EyePoint Inc in Q4 2023, an estimated $31.7M increase.
  • Cormorant Asset Management's biggest Q4 2023 reduction was Apellis Pharmaceuticals, cutting an estimated $69.8M.
  • Cormorant Asset Management fully exited Structure Therapeutics in Q4 2023, selling an estimated $53.3M.
  • Cormorant Asset Management's ten largest holdings make up 63% of its $2.09B portfolio in Q4 2023.
  • Cormorant Asset Management opened 9 new positions and closed 10 in Q4 2023.
  • Cormorant Asset Management's portfolio value rose 22% quarter-over-quarter to $2.09B.

Based on Cormorant Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.